Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 5;5(4):650–660. doi: 10.1002/hep4.1654

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Fig. 2 — Transplant‐free survival according to MELD, Child‐Pugh, ALBI, and CLIF‐C AD score. MELD, Child‐Pugh, ALBI, and CLIF‐C AD scores were all able to stratify patients according to TFS following TIPS implantation. Patients with a MELD score > 12 showed significantly reduced TFS of 21.0 (14.4‐27.6) months compared with 48.0 (40.8‐55.2) months in patients with a MELD score of ≤ 12 (P < 0.001). TFS was 63.0 (45.9‐80.1) versus 37.0 (30.5‐43.5) versus 27.0 (19.0‐35.0) months in patients with Child‐Pugh stadiums A, B and C, respectively (P < 0.001). TFS was 65.0 (48.3‐81.7) months in ALBI stadium 1, 41.0 (35.4‐46.6) months in ALBI stadium 2, and 29.0 (20.1‐37.9) months in ALBI stadium 3 (P < 0.001). TFS declined with increasing CLIF‐C AD score from 67.0 (58.3‐75.7) to 30.0 (23.0‐37.0) to 11 (0‐22.2) months in patients with a CLIF‐C AD score of ≤ 45, 46‐59, and ≥ 60, respectively (P < 0.001).